← Back to headlines
Merck Reports Positive Phase 3 Data for RSV Vaccine ENFLONSIA
Merck announced positive results from its phase 3 second-season RSV data for the vaccine ENFLONSIA, indicating continued efficacy.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
